Endocrine Abstracts

Background: MiRNAs are small non-coding RNAs, which regulate biological and pathological processes, including organogenesis, apoptosis, cell proliferation and differentiation. Considering the complexity of the parathyroid cancer (PC) diagnosis, discovering of new markers of the disease, which may help to evaluate the prognosis before surgical treatment, becomes an important problem. We studied the differences in miRNA expression profile in the blood serum between patients with...

Parathyroid glands are critical not only for regulation of the phosphorous-calcium metabolism, but also have a key role in the function of nervous, cardiovascular, digestive and other human body systems. Parathyroids are capable of accumulating the isotopes of cesium, strontium and radioactive iodine, which can lead to parathyroid cell damage and emergence of glandular dysfunction. Significant radioactive environmental releases and fallout after the Chernobyl NPP accident in 1...

Background: Hypoparathyroidism (HP), a condition of parathyroid hormone (PTH) deficiency, leads to abnormal calcium metabolism. Standard of care (SOC), ie, large amounts of calcium and active vitamin D, leads to hypercalciuria and increased calcium x phosphate. Daily Natpara, PTH(1-84), injections reduced calcium and active vitamin D doses but not 24-hour urinary calcium (uCa) excretion or incidence of hypo- and hypercalcemia due to its 3-hour half-life (Natpara label). NIH st...

Pseudohypoparathyroidism (PHP) and related disorders lead to a wide spectrum of abnormal physical characteristics, neurocognitive and endocrine abnormalities that share a common PTH/PTHrP signaling pathway. The clinical and molecular overlap of PHP and related disorders lead to difficulties in clinical and molecular diagnosis which prompt to the possibility of incorrect management of these patients. PHP (including all subtypes), pseudoPHP, acrodysostosis and progressive osseou...

Chronic hypoparathyroidism (HypoPT) is a rare disease associated with a variety of symptoms and diminished health-related quality of life (HRQoL). This study aimed to characterise and quantify the symptom burden, HRQoL, and overall disease impact in patients receiving recombinant human parathyroid hormone (rhPTH1-84, Natpar®) for inadequately controlled HypoPT and in symptomatic patients receiving standard therapy (ST; calcium and/or vitamin D supplements). A w...

Hypoparathyroidism is a rare disorder characterised by hypocalcaemia and insufficient or undetectable parathyroid hormone (PTH). Recombinant human PTH, rhPTH(1-84), has been approved in the United States and Europe as an adjunctive treatment for adult patients with hypoparathyroidism. When hypoparathyroidism is established, long-term administration of rhPTH(1-84) is a treatment option. Thus, long-term safety and efficacy data for rhPTH(1-84) are needed. To this end, we evaluat...

PARADIGHM™, a global, prospective, observational registry of patients with chronic hypoparathyroidism (HPT), began enrolment in 2013 to collect data on the natural history of chronic HPT (ClinicalTrials.gov NCT01922440). Since initiation, recombinant human PTH, rhPTH(1-84), has been approved in the United States and Europe as an adjunctive treatment for adult patients with HPT. The protocol for the registry (now a European Medicines Agency–designated postm...

The kidney is an important target of primary hyperparathyroidism (PHPT). The 4th International Workshop for the management of Asymptomatic PHPT included the presence of hypercalciuria (24-h urinary calcium > 400 mg/day) and increased stone risk by biochemical stone risk profile as criteria for surgery. Increased stone risk profile was defined as at least one between ßCaOx>4 and ßHPO4>2, as defined in literature in a different study population. The aim of ...

Hypoparathyroidism is a disorder of mineral homoeostasis due to parathyroid hormone (PTH) deficiency. Conventional treatment with oral Ca and calcitriol may maintain serum Ca levels but does not replace other physiologic PTH effects. RACE is an ongoing open-label study of recombinant human PTH1-84 (rhPTH1-84) for hypoparathyroidism treatment in adults (ClinicalTrials.gov NCT01297309). Patients initially received rhPTH1-84 25 or 50 μg/day subcutaneously, with 25-μg in...

Background: Parathyroid hormone (PTH) secretion in response to hypocalcemia was found to be altered in people living with HIV (PLWH) and HIV infection has therefore been acknowledged as a potential reason for hypoparathyroidism (HPO).Aim: To describe the prevalence of HPO in a population of PLWH.Methods: Monocentric, retrospective sub-study of the Munich ArcHIV cohort.Results: 579 patients (461 men (79.6%)) w...

Introduction: Hypoparathyroidism (hypoPT) is characterized by inadequately low circulating concentrations of parathyroid hormone (PTH) followed by low calcium and increased phosphate levels in the blood. Patients with hypoPT suffer from a number of complications and complaints including infections, neuro-psychiatric diseases, abnormal bone architecture impaired muscle function and reduced quality of life. Due to the complexity of the various clinical manifestations there is a ...

The G protein-coupled calcium sensing receptor (CaSR), widely expressed on the surface of parathyroid chief cells and in the kidney, plays a central role in calcium homeostasis. Activating mutations of CaSR gene are responsible for autosomal dominant hypocalcemia (ADH), a rare disorder caused by hypocalcemia, hyperphosphatemia, hypercalciuria and inadequately low concentration of parathyroid hormone (PTH). In this study, we report a family affected by ADH. The proband...